◆ NeutralADMA
$ADMA Securities: Suffer Losses on Your ADMA Biologics Investment? BFA Law Reminds Investors of the Securities Fraud Lawsuit to Recover Losses
GlobeNewswire Inc.·
ADMA Biologics faces a securities fraud class action lawsuit after its stock plummeted following Culper Research's allegations of channel stuffing. The company allegedly inflated its 2025 revenue growth from -3% to +20% by inducing distributors to overstock its flagship product ASCENIV through rebates and extended payment terms. The stock dropped 29% cumulatively following the March 2026 revelations and subsequent analyst downgrades.
Read Full Article at GlobeNewswire Inc. →